The experience of allogeneic hematopoietic stem cell transplantation in a patient with X-linked adrenoleukodystrophy
Transfusion and Apheresis Science, ISSN: 1473-0502, Vol: 59, Issue: 1, Page: 102583
2020
- 5Citations
- 20Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- Captures20
- Readers20
- 20
Article Description
X-linked adrenoleukodystrophy (X-ALD), a progressive neurometabolic disorder that is caused by a defect in the gene ABCD1 (ATP-binding cassette, subfamily D, member 1), which encodes the peroxisomal ABC half-transporter ALD protein. Recently, allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only therapy known to prevent disease progression. In this study, we would like to present our experience of alloHSCT for X-ALD from a HLA matched related sibling by the use of reduced intensity conditioning regimen composed of fludarabine, busulfan and ATG which allows us to reduce procedure-related toxicity and prevent mortality while achieving a curative effect.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1473050219301144; http://dx.doi.org/10.1016/j.transci.2019.06.019; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85069730441&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/31350055; https://linkinghub.elsevier.com/retrieve/pii/S1473050219301144; https://dx.doi.org/10.1016/j.transci.2019.06.019
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know